Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Images

 
There are currently no images for PD-L1 (156-B7).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity
Format
Carrier-Free

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Summary

Details of Functionality
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein
Human PD-L1
(Phe19-Thr239)
Accession # Q9NZQ7
DIEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
N-terminal Sequence
Phe19
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
Gene
CD274
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Theoretical MW
52 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
70-75 kDa, reducing conditions
Publications
Read Publications using
156-B7 in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

  • Avelumab
  • B7-H
  • B7H1
  • B7-H1
  • B7H1PDCD1L1
  • CD274 antigenMGC142294
  • CD274 molecule
  • CD274
  • PDCD1L1
  • PDCD1LG1
  • PDCD1LG1MGC142296
  • PDL1
  • PD-L1
  • PD-L1B7 homolog 1
  • PDL1PDCD1 ligand 1
  • programmed cell death 1 ligand 1
  • Programmed death ligand 1

Background

PD-L1, also known as B7-H1, is one of the ligands for PD-1 and plays a critical role in the regulation of T cell immunity (1-6). The PD-1:PD-L1 interaction initiates a negative signaling cascade in T cells leading to inhibition of T cell activation (2,5,7,8). PD-L1 provides a molecular stop signal to the adaptive immune system helping to distinguish between self and foreign antigens. PD-L1 also plays a role in the development of immune tolerance by promoting T cell anergy (1,5) and enhancing regulatory T cell development (8). In addition, PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (7,9) and inhibits the development of Th17 cells (8). Many cancers exhibit upregulated PD-L1 protein expression, and several cancers with high levels of PD-L1 have been associated with increased tumor aggressiveness and poor prognosis. Using new therapeutics that block the PD-L1:PD-1 interaction has proven successful in the clinic for many cancer types and has sparked great interest in the field of cancer immunotherapy.

The PD-L1 protein is an approximately 65 kDa transmembrane glycoprotein belonging to the B7 family of immune regulatory molecules (10). Mature human PD-L1 protein consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (11). Within the ECD, human PD-L1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (12). PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (10,13,14,16), keratinocytes (9,11), endothelial and intestinal epithelial cells (2,9), as well as a variety of carcinomas and melanoma (12,16).

  1. Tsushima, F. et al. (2007) Blood 110:180.
  2. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
  3. Azuma, T. et al. (2008) Blood 111:3635.
  4. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
  5. Park, J.-J. et al. (2010) Blood 116:1291.
  6. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
  7. Chen, L. et al. (2007) J. Immunol. 178:6634.
  8. Herold, M. et al. (2015) J. Immunol. 195:3584.
  9. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
  10. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
  11. Dong, H. et al. (1999) Nat. Med. 5:1365.
  12. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
  13. Tamura, H. et al. (2001) Blood 97:1809.
  14. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
  15. Cao, Y. et al. (2010) Cancer Res. 71:1235.
  16. Dong, H. et al. (2002) Nat. Med. 8:793.

Customers Who Viewed This Item Also Viewed...

AF1086
Species: Hu
Applications: WB, Flow, IHC, Block, CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta)
MAB1224
Species: Hu
Applications: WB, Flow, IHC, CyTOF-ready
NBP2-25255
Species: Hu, Mu
Applications: WB, Flow, IHC, IHC-P
MAB7158
Species: Hu, Mu
Applications: WB, IHC
NB100-524
Species: Hu, Mu
Applications: WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Flow-IC
NBP2-45041
Species: Hu, Po
Applications: Flow, IHC, IHC-Fr, IF
NBP1-49045
Species: Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Cell Depl, CyTOF-ready, InhibTFunc
NBP1-19371
Species: Hu, Mu, Rt, Ca, Rb
Applications: WB, Simple Western, Flow, ICC/IF, IHC, IHC-Fr, IHC-P
NBP2-25208
Species: Hu, Mu, Rt
Applications: WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, KO
NBP1-92684
Species: Hu, Mu, Rt, Po, Bv, Eq
Applications: WB, ICC/IF, IHC
MAB342
Species: Hu
Applications: WB, AgAct
NB100-39002
Species: Hu, Mu, Rt, Bv
Applications: WB, Flow, IB, ICC/IF, IHC, IHC-P, IP, Single-Cell Western

Publications for PD-L1 (156-B7)(15)

We have publications tested in 3 confirmed species: Human, N/A, Yeast.

We have publications tested in 3 applications: Bioassay, ELISA (Standard), Flow Cytometry.


Filter By Application
Bioassay
(8)
ELISA (Standard)
(3)
Flow Cytometry
(1)
All Applications
Filter By Species
Human
(9)
N/A
(1)
Yeast
(1)
All Species
Showing Publications 1 - 10 of 15. Show All 15 Publications.
Publications using 156-B7 Applications Species
L Sun, CW Li, EM Chung, R Yang, YS Kim, AH Park, YJ Lai, Y Yang, YH Wang, J Liu, Y Qiu, KH Khoo, J Yao, JL Hsu, JH Cha, LC Chan, JM Hsu, HH Lee, SS Yoo, MC Hung Targeting glycosylated PD-1 induces potent anti-tumor immunity Cancer Res., 2020;0(0):. 2020 [PMID: 32156778] (Bioassay, Human) Bioassay Human
B Cembrola, V Ruzza, F Troise, ML Esposito, E Sasso, V Cafaro, M Passariell, F Visconte, M Raia, L Del Vecchi, AM D'Alise, R Cortese, E Scarselli, N Zambrano, C De Lorenzo, A Nicosia Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries Biomed Res Int, 2019;2019(0):6051870. 2019 [PMID: 31976323] (Yeast) Yeast
KJ Carpenter, AC Valfort, N Steinauer, A Chatterjee, S Abuirqeba, S Majidi, M Sengupta, RJ Di Paolo, LP Shornick, J Zhang, CA Flaveny LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer Sci Rep, 2019;9(1):19530. 2019 [PMID: 31863071] (Bioassay, Human) Bioassay Human
W Fu, C Lei, S Liu, Y Cui, C Wang, K Qian, T Li, Y Shen, X Fan, F Lin, M Ding, M Pan, X Ye, Y Yang, S Hu CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity Nat Commun, 2019;10(1):4355. 2019 [PMID: 31554797]
JK Fierle, J Abram-Sali, M Brioschi, M deTiani, G Coukos, SM Dunn Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery Sci Rep, 2019;9(1):12815. 2019 [PMID: 31492910] (Bioassay, Human) Bioassay Human
A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight, 2018;3(19):. 2018 [PMID: 30282824] (Flow Cytometry, Human) Flow Cytometry Human
UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy Anticancer Res., 2017;37(4):1947-1955. 2017 [PMID: 28373465] (ELISA (Standard)) ELISA (Standard)
E Burova, A Hermann, J Waite, T Potocky, V Lai, S Hong, M Liu, O Allbritton, A Woodruff, Q Wu, A D'Orvillie, E Garnova, A Rafique, W Poueymirou, J Martin, T Huang, D Skokos, J Kantrowitz, J Popke, M Mohrs, D MacDonald, E Ioffe, W Olson, I Lowy, A Murphy, G Thurston Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice Mol. Cancer Ther, 2017;0(0):. 2017 [PMID: 28265006] (Bioassay, N/A) Bioassay N/A
Robert L Ferris Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk Oncoimmunology, 2016;5(10):e1200778. 2016 [PMID: 27853635] (Bioassay) Bioassay
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells Sci Rep, 2016;6(0):36722. 2016 [PMID: 27824138] (ELISA (Standard), Human) ELISA (Standard) Human
Show All 15 Publications.

Reviews for PD-L1 (156-B7) (0)

There are no reviews for PD-L1 (156-B7). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for PD-L1 (156-B7) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Customers Who Bought This Also Bought

PD-L1 Antibody
NBP1-76769

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF and receive a gift card or discount.

Bioinformatics

Gene Symbol CD274
Uniprot